Keyphrases
Prognostic Significance
100%
Homozygous Deletion
100%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
100%
CDKN2A mutation
100%
IDH-mutant Astrocytoma
100%
CDKN2A Deletion
33%
Overall Survival
22%
Tumor
11%
Publicly Available
11%
Progression-free
11%
Astrocytoma
11%
Detrimental Effects
11%
Survival Outcomes
11%
Survival Disparities
11%
Progression-free Survival
11%
Effects on Survival
11%
Copy number Variation
11%
Molecular Signature
11%
Aggressive Behavior
11%
Prognostic Implications
11%
Histomorphology
11%
Grading of Recommendations
11%
Pathogenic mutations
11%
Grading Scheme
11%
Inactivating Mechanism
11%
2021 WHO Classification
11%
WHO Classification of CNS Tumors
11%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Progression Free Survival
100%
Allele
50%
Copy-Number Variation
50%
Aggression
50%
Medicine and Dentistry
Oligoastrocytoma
100%
Progression Free Survival
28%
Overall Survival
28%
Neoplasm
14%
Allele
14%
Central Nervous System Tumor
14%
Aggression
14%
Copy Number Variation
14%
Pharmacology, Toxicology and Pharmaceutical Science
Astrocytoma
100%
Overall Survival
28%
Progression Free Survival
28%
Neoplasm
14%
Central Nervous System Tumor
14%
Neuroscience
Astrocytoma
100%
Tumor of Central Nervous System
14%
Copy Number Variation
14%
Aggression
14%